A Phase 4 interventional study of iStent inject and Travoprost in Open-angle Glaucoma, sponsored by Glaukos Corporation. Completed at 1 site in Armenia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-08.
Sponsored by Glaukos Corporation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 15th largest by enrollment of the 45 interventional ones that give a count, is one of 9 that started in 2011, is one of 22 in phase 4, and was the 29th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.
Browse Glaucoma, Open-Angle studies →2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:
Jonathon Myers · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 45+
By country, each count listing its studies:
Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 9 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 196 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 135 across the 45 interventional studies. Of the 43 that completed or were terminated, 23 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 46 have an industry lead sponsor. The 10 most frequent:
Glaukos Corporation is the lead sponsor of 67 studies on the registry; 14 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.
43 studies in Glaucoma, Open-Angle by Glaukos Corporation: 7 open now, 10 under way, 2 of them phase 3. Of 30 finished, 8 (27%) have results posted.
Among the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation, this one is the 11th largest by enrollment of the 38 interventional ones that give a count, is one of 6 that started in 2011, is one of 12 in phase 4, and was the 11th registered.
Glaukos Corporation’s Glaucoma, Open-Angle studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Glaukos Corporation’s 43 in Glaucoma, Open-Angle:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluation of the intraocular pressure (IOP) lowering effect of two iStent inject devices versus medical therapy in eyes of subjects with primary open-angle glaucoma, pseudoexfoliative glaucoma, or ocular hypertension naïve to medical and surgical therapy.
Evaluation of the intraocular pressure (IOP) lowering effect of two iStent inject devices versus medical therapy in eyes of subjects with primary open-angle glaucoma, pseudoexfoliative glaucoma, or ocular hypertension naïve to medical and surgical therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Implantation of two iStent inject devices
Device: iStent inject
Travoprost drops
Drug: Travoprost
Implantation of two iStent inject devices
Travoprost drops
Change from screening in mean diurnal IOP (mm Hg) at the Month 12 visit.
Time frame: 12 months
Change in mean diurnal IOP vs. screening
Time frame: Month 24
Change in screening in time-wise IOPs
Time frame: Various Month 12-60
Proportion of responders
A responder is defined as a subject with a certain target IOP value or a certain reduction of IOP as compared to screening. In the iStent inject group, a responder must not be on an ocular hypotensive medications or have had a postoperative procedure to reposition or remove stent(s) prior to the visit. Due to the lack of a complete consensus on the definition of a clinical responder, a set of target IOP values (e.g., downwards from 22 mm Hg in steps of 1 mm Hg) and reductions of IOP (e.g., downwards from the highest reduction in IOP in steps of 5%) will be evaluated.
Time frame: Various 12-60 months
Adverse event reporting
Rate of ocular adverse events through 60 months * Findings from IOP, best corrected visual acuity, visual field * Findings from slit-lamp, fundus and gonioscopic examinations
Time frame: 0-60 months
Ran from Sep 2011 to primary completion in Mar 2019, 90 months.
Of 45 phase 4 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's 90 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Travoprost